Press Release

Press Release - New LEQSELVI® (deuruxolitinib) two-year data at EADV Congress 2026 - Long-term safety profile consistent with prior data; no major cardiovascular events reported at FDA-approved dose - Durable efficacy: 93.9% of responders maintained scalp hair regrowth at Week 108 - 76.6% of baseline nonresponders achieved response by Week 52; 96.8% maintained response at Week 108 - LEQSELVI is an oral JAK1/JAK2 inhibitor approved for severe alopecia areata in adults - Safety warnings include infection risk, cardiovascular events in 50+ with risk factors, and blood test monitoring - Data supports LEQSELVI as a long-term treatment option for severe alopecia areata